{"id":"naloxone-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Acute withdrawal syndrome"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Diaphoresis"},{"rate":null,"effect":"Agitation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naloxone competitively binds to opioid receptors (mu, delta, and kappa) with higher affinity than opioids, displacing opioids from these receptors and rapidly reversing their effects. This mechanism restores normal respiratory function and consciousness in opioid overdose. The infusion formulation allows for sustained reversal of long-acting opioids and prevention of re-sedation.","oneSentence":"Naloxone is an opioid antagonist that blocks opioid receptors to reverse opioid overdose and respiratory depression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:35.781Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid overdose reversal"},{"name":"Opioid-induced respiratory depression"}]},"trialDetails":[{"nctId":"NCT04975347","phase":"PHASE1","title":"Opioid Antagonism in Individuals Ascertained Through the Partners HealthCare Biobank","status":"COMPLETED","sponsor":"Stephanie B. Seminara, MD","startDate":"2022-06-03","conditions":"Reproductive Disorders","enrollment":47},{"nctId":"NCT04600089","phase":"PHASE2","title":"Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI","status":"RECRUITING","sponsor":"Sam Tyagi","startDate":"2020-12-08","conditions":"Descending Aortic Dissection, Postoperative Pain, Thoracoabdominal Aortic Aneurysm","enrollment":30},{"nctId":"NCT06306391","phase":"PHASE1","title":"Pharmacokinetics of Intravenous and Intranasal Formulations of Naloxone in Healthy Volunteers.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2024-03-05","conditions":"Healthy","enrollment":8},{"nctId":"NCT06666621","phase":"PHASE4","title":"Endogenous Opioid Response to Injections","status":"RECRUITING","sponsor":"Middle Tennessee Research Institute","startDate":"2024-08-22","conditions":"Low Back Pain, Zygapophyseal Joint Arthritis","enrollment":33},{"nctId":"NCT02461927","phase":"PHASE1, PHASE2","title":"Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2015-01-01","conditions":"Major Depressive Disorder, Alcohol Use Disorder","enrollment":65},{"nctId":"NCT03305549","phase":"NA","title":"Recovery After Dialysis-Requiring Acute Kidney Injury","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2017-09-29","conditions":"Acute Kidney Injury","enrollment":16},{"nctId":"NCT05338632","phase":"PHASE1","title":"Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2022-06-24","conditions":"Opioid Induced Respiratory Depression, Chronic Opioid Use","enrollment":24},{"nctId":"NCT05940324","phase":"PHASE2","title":"Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-02-24","conditions":"Obsessive-Compulsive Disorder","enrollment":150},{"nctId":"NCT01950520","phase":"PHASE2","title":"Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-02-07","conditions":"Healthy Volunteers","enrollment":47},{"nctId":"NCT01952782","phase":"PHASE1","title":"Neuropeptides in Human Reproduction","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-04-30","conditions":"Hypogonadotropic Hypogonadism","enrollment":61},{"nctId":"NCT04562779","phase":"EARLY_PHASE1","title":"Inpatient Single Dose Interventions for Alcohol Use Disorder","status":"COMPLETED","sponsor":"Denver Health and Hospital Authority","startDate":"2021-01-19","conditions":"Alcohol Use Disorder, Severe","enrollment":44},{"nctId":"NCT02684669","phase":"PHASE2","title":"Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia During a Burn Injury","status":"COMPLETED","sponsor":"mads u werner","startDate":"2016-02","conditions":"Healthy Subjects","enrollment":80},{"nctId":"NCT02976337","phase":"PHASE2","title":"Effect of High-dose Naloxone Following Third Molar Extraction","status":"COMPLETED","sponsor":"mads u werner","startDate":"2017-10-12","conditions":"Healthy Subjects, Hyperalgesia, Inflammations, Endodontic","enrollment":23},{"nctId":"NCT01992146","phase":"PHASE2","title":"Effect of High-dose Naloxone Infusion on Pain and Hyperalgesia in Patients Following Groin-Hernia Repair.","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2015-11-11","conditions":"Central Nervous System Sensitization, Pain, Hyperalgesia","enrollment":9},{"nctId":"NCT06130527","phase":"NA","title":"Comparison of the Effects of Nicardipine and Remifentanil on Surgical Visual Field","status":"UNKNOWN","sponsor":"Erol Karaaslan","startDate":"2023-11-30","conditions":"Other Complications of Surgical and Medical Procedures","enrollment":64},{"nctId":"NCT04034004","phase":"EARLY_PHASE1","title":"Chronic Low Back Pain and Meditation","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2021-01-01","conditions":"Pain","enrollment":88},{"nctId":"NCT05301712","phase":"PHASE4","title":"A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Stroke","status":"COMPLETED","sponsor":"Samjin Pharmaceutical Co., Ltd.","startDate":"2018-08-07","conditions":"Stroke, Acute","enrollment":446},{"nctId":"NCT04977674","phase":"EARLY_PHASE1","title":"Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine","status":"COMPLETED","sponsor":"King's College London","startDate":"2021-09-27","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":27},{"nctId":"NCT05360030","phase":"NA","title":"Mechanism of Analgesic Effect on Prolonged Continuous Theta Burst Stimulation","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-14","conditions":"Chronic Pain, rTMS","enrollment":45},{"nctId":"NCT04365985","phase":"PHASE2","title":"Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19","status":"TERMINATED","sponsor":"Corewell Health East","startDate":"2020-04-29","conditions":"COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS)","enrollment":70},{"nctId":"NCT03757455","phase":"NA","title":"ERAS Protocol in Pancreaticoduodenectomy and Total Pancreatectomy","status":"TERMINATED","sponsor":"Tampere University Hospital","startDate":"2020-09-01","conditions":"Pancreatic Cancer, Surgery--Complications, Pancreatic Fistula","enrollment":35},{"nctId":"NCT03096353","phase":"EARLY_PHASE1","title":"Sensory and Opioid Mechanisms of Affective Touch","status":"COMPLETED","sponsor":"National Center for Complementary and Integrative Health (NCCIH)","startDate":"2017-08-01","conditions":"Pain, Touch","enrollment":29},{"nctId":"NCT01531439","phase":"NA","title":"Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion Surgery","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2011-11","conditions":"Pain, Postoperative, Postoperative Nausea and Vomiting, Scoliosis","enrollment":84},{"nctId":"NCT03419858","phase":"EARLY_PHASE1","title":"The Role of Opioidergic Systems in Breathing Based Analgesia","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2017-03-13","conditions":"Pain","enrollment":60},{"nctId":"NCT02437344","phase":"PHASE2","title":"Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2015-01","conditions":"Opioid Dependence","enrollment":16},{"nctId":"NCT02307721","phase":"PHASE1, PHASE2","title":"Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2014-12","conditions":"Drug Overdose","enrollment":12},{"nctId":"NCT03658330","phase":"PHASE2","title":"Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder","status":"COMPLETED","sponsor":"VA Connecticut Healthcare System","startDate":"2016-05","conditions":"Major Depressive Disorder, Alcohol Use Disorder","enrollment":5},{"nctId":"NCT02405988","phase":"NA","title":"Pharmacodynamics and Arteriovenous Differences of Naloxone in Healthy Participants Exposed to an Opioid","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2015-04","conditions":"Drug Overdose","enrollment":12},{"nctId":"NCT02911597","phase":"PHASE1","title":"Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2016-09","conditions":"Depression","enrollment":16},{"nctId":"NCT02885948","phase":"PHASE4","title":"The Use of Low Dose Prophylactic Naloxone Infusion to Prevent Respiratory Depression With Intrathecal Morphine.","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2016-04","conditions":"Respiratory Depression","enrollment":96},{"nctId":"NCT01071057","phase":"PHASE2, PHASE3","title":"Naloxone for the Treatment of Opioid-Induced Pruritus","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2010-12","conditions":"Pruritus","enrollment":92},{"nctId":"NCT00679614","phase":"PHASE3","title":"Effect of Combined Use of Naloxone and Tramacet on Postop Analgesia in Elderly Patients Having Joint Replacement Surgery","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2007-12-17","conditions":"Hip Arthroplasty, Knee Arthroplasty, Spinal Anesthesia","enrollment":45},{"nctId":"NCT00665262","phase":"PHASE4","title":"The Effect of the Combined Use of Naloxone and Tramacet on Postoperative Analgesia in the Elderly","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2007-12-17","conditions":"Arthroplasty","enrollment":10},{"nctId":"NCT00330343","phase":"PHASE2","title":"Optimal Dose of Prophylactic Naloxone in Reducing Opioid-Induced Side Effects in Children/Adolescents","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2004-05","conditions":"Pain, Nausea, Pruritus","enrollment":75},{"nctId":"NCT00667771","phase":"EARLY_PHASE1","title":"The Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol Infusion","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2008-04-22","conditions":"Alcohol Dependence, Alcoholism","enrollment":70},{"nctId":"NCT03014843","phase":"NA","title":"The Effect of Naloxone and Methylnaltrexone on Esophageal Sensitivity in Health","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2013-10","conditions":"Endogenous and Esophageal Sensitivity","enrollment":12},{"nctId":"NCT02856087","phase":"NA","title":"The Effect of Ultra-low-dose Naloxone on Remifentanil-induced Postoperative Hyperalgesia - A Randomized Controlled Study","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-11","conditions":"Pain","enrollment":92},{"nctId":"NCT00908089","phase":"PHASE4","title":"TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"University of Helsinki","startDate":"2003-03","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT01935206","phase":"PHASE1","title":"Effect of High Dose Naloxone on Secondary Hyperalgesia","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2013-06","conditions":"Hyperalgesia, Pain, Naloxone","enrollment":15},{"nctId":"NCT01750060","phase":"PHASE1","title":"Pharmacokinetic Characterization of the Active, Separated System With PK Controller (Fentanyl Iontophoretic Transdermal System, 40 Mcg Fentanyl Per Activation).","status":"COMPLETED","sponsor":"Incline Therapeutics, Inc.","startDate":"2012-12","conditions":"Pain, Postoperative","enrollment":54},{"nctId":"NCT01191645","phase":"PHASE4","title":"Opioid Effects on Swallowing and Esophageal Sphincter Pressure","status":"COMPLETED","sponsor":"Region Örebro County","startDate":"2010-10","conditions":"Opioid Induced Pharyngeal and Esophageal Dysfunction","enrollment":14},{"nctId":"NCT00669175","phase":"","title":"Safety and Efficacy of a Low Dose Naloxone Infusion in NICU Patients","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2008-02","conditions":"Opioid Tolerance, Pain","enrollment":25},{"nctId":"NCT00714558","phase":"PHASE1","title":"Pharmacokinetics of Fentanyl Following Intravenous and Oral Routes of Administration in Healthy Volunteers","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"2003-04","conditions":"Biological Availability","enrollment":18},{"nctId":"NCT00714584","phase":"PHASE1","title":"Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"2003-05","conditions":"Biological Availability","enrollment":18},{"nctId":"NCT00829777","phase":"PHASE1","title":"Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects","status":"COMPLETED","sponsor":"California Pacific Medical Center Research Institute","startDate":"2009-03","conditions":"Opiate Addiction","enrollment":8},{"nctId":"NCT00286052","phase":"PHASE3","title":"Impact of Low Dose Naloxone on Fentanyl Requirements in Pediatric ICU Patients","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2002-12","conditions":"Opioid Tolerance","enrollment":128}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":333,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Naloxone infusion","genericName":"Naloxone infusion","companyName":"Middle Tennessee Research Institute","companyId":"middle-tennessee-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naloxone is an opioid antagonist that blocks opioid receptors to reverse opioid overdose and respiratory depression. Used for Opioid overdose reversal, Opioid-induced respiratory depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}